Scott Biller's Email & Phone

Dr. Biller joined Agios as Chief Scientific Officer in 2010, with more than 25 years of drug discovery and development experience. Most recently, he was vice president and head of global discovery chemistry at the Novartis Institutes for Biomedical Research (NIBR). Prior to that, Dr. Biller held the positions of vice president, pharmaceutical candidate optimization at the Bristol Myers Squibb (BMS) Pharmaceutical Research Institute and executive director of drug discovery chemistry for the BMS research site in Lawrenceville, NJ. Among his other key leadership positions at BMS, Dr. Biller was the executive director of metabolic diseases chemistry. He contributed to robust pipelines at both BMS and Novartis, culminating in one medicine launched worldwide (Onglyza for the treatment of Type 2 diabetes) and three additional drugs reaching Phase 3 clinical development. Dr. Biller earned an S.B. degree in chemistry at MIT, a Ph.D. in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University in natural product synthesis.